Clinical Trials

  • New IDEAS: Brain Imaging Study for Memory Loss

    Principal Investigator:

    Lawrence Sterling Honig, MD, PhD
    This is a research study for persons with memory problems that examines the utility of performing positron emission tomography (PET) scans for the brain amyloid protein found in Alzheimer's disease.

  • Parkinson's Progression Markers Initiative (PPMI)

    Principal Investigator:

    Sarah A. O'Shea, MD
    The Parkinson's Progression Markers Initiative (PPMI) seeks to uncover insights into Parkinson's disease (PD) onset and progression that could transform how we diagnose, treat, and potentially prevent PD. PPMI has already contributed to a new understanding around disease biology and experience, and its findings and design have led to more efficient clinical research. Now PPMI is looking to bring together a larger and more diverse group of individuals both with and without PD who can help contribute to a more detailed look into the way the disease develops and changes over time. The study will...

  • ProChocolate Study - Patients with Multiple Sclerosis (MS) and Family Members of Patients with MS

    Principal Investigator:

    Rebecca Straus Farber, MD
    We are currently recruiting individuals with Multiple Sclerosis (MS), first-degree family members of persons with MS, and healthy individuals to take part in our research on the effects of probiotics. Our goal is to better understand how the health of the gut microbiome influences the immune system.

  • Resource for Early Onset Alzheimer's Disease Research (READR)

    Principal Investigator:

    Christiane Reitz, MD, PhD
    We are recruiting families with members under the age of 65 who have dementia or are experiencing memory problems. Our initial screening can be completed in person or over the phone. The evaluation will take about 1 to 1.5 hours per person and includes a: 1. Blood sample (5 tablespoons) or saliva (1 teaspoon) collection: These blood samples will allow us to examine genes to identify causative mutations. 2. Brief Neuropsychological Assessment. 3. Medical History: A research physician will collect basic medical information on you and your family. This assessment will provide information on...

  • SAGE HD-201

    Principal Investigator:

    Sarah A. O'Shea, MD
    The DIMENSION Study is evaluating the safety and effect on cognitive symptoms of an investigational oral drug in adults with early Huntington's disease. Cognitive symptoms may include difficulty paying attention or trouble thinking through steps of an activity or complex problems. Symptoms may also include difficulty planning, remembering, and staying on task, impaired judgment, and difficulty multi-tasking. There will be an open-label extension (OLE) study, which is planned to begin later in 2022. Participants who are interested can speak to the study team. To be eligible for the study, you...

  • Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP) (PROGRESS)

    Principal Investigator:

    Thomas H. Brannagan III, MD
    To be in this study you must have Diabetic Peripheral Neuropathic (DPN) and be 18 years of age, inclusive, with the presence of bilateral pain in lower extremities due to DPN for at least 6 months prior to Screening and be in a stable regimen for the treatment of T1DM or T2DM for 3 months prior to Screening.

  • Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP) (PROGRESS)

    Principal Investigator:

    Thomas H. Brannagan III, MD
    To be in this study you must have Diabetic Peripheral Neuropathic (DPN) and be 18 years of age, inclusive, with the presence of bilateral pain in lower extremities due to DPN for at least 6 months prior to Screening and be in a stable regimen for the treatment of T1DM or T2DM for 3 months prior to Screening.

  • Study of Alogabat in Children and Adolescents with Angelman Syndrome (AS)

    Principal Investigator:

    Jennifer M. Bain, MD, PhD
    This is a Phase IIA Multicenter, open-label, 12-week study to investigate the pharmacokinetics and safety and to provide proof of mechanism of the drug, Alogabat (RO7017773) in children and adolescents aged 5-17 years old with Angelman Syndrome with the deletion genotype.

  • Study of Ampreloxetine in Treating Orthostatic Hypotension in Multiple System Atrophy (MSA)

    Principal Investigator:

    Sheng-Han Kuo, MD
    You may be eligible to take part in the study because you have a diagnosis of Multiple System Atrophy (MSA) with the symptoms of neurogenic Orthostatic Hypotension (nOH). MSA is a rare disorder in adults that progresses rapidly and ultimately is a fatal neurodegenerative disease. It is characterized by autonomic failure affecting blood pressure regulation, movement and balance. Autonomic failure occurs when the autonomic nervous system, which controls functions responsible for well-being and maintaining balance, does not regulate properly. The main purpose of this study is to look at...

  • Study of AZD9574 in Patients with Brain Cancer

    Principal Investigator:

    Maria Diaz Ordonez, MD
    The main purpose of this study is to determine a dose of AZD9574 that is safe and tolerable (does not cause side effects that could prevent people from taking the drug) when given alone or in combination with temozolomide. The study will also evaluate how much of the study drug is in your blood at various times. In addition, the action of the study drug will be evaluated by measuring specific chemicals in the blood. All parts of this study are experimental which means AZD9574 is not approved by the U.S. Food and Drug Administration (FDA). This is the first time AZD9574 has been tested in...

Pages